ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma (ABC-lung)

  • STATUS
    Recruiting
  • End date
    Mar 30, 2023
  • participants needed
    95
  • sponsor
    European Thoracic Oncology Platform
Updated on 24 March 2022
Accepts healthy volunteers

Summary

ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).

Details
Condition EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
Treatment carboplatin, Paclitaxel, bevacizumab, Pemetrexed, Atezolizumab
Clinical Study IdentifierNCT04245085
SponsorEuropean Thoracic Oncology Platform
Last Modified on24 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients (male/female) must be ≥18 years of age
Chemotherapy naïve, non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV. Patients who have received previous adjuvant or neoadjuvant chemotherapy are eligible if the date of last dose of treatment was at least 12 months before randomisation
Known EGFR mutations genotypes by tissue or ctDNA, patients with common mutations (L858R or Del19) and other rare mutations (e.g. S768I, G719X) are eligible
Measurable or evaluable disease by RECIST v1.1
Disease progression (during or after) or unacceptable side effects from prior treatment with at least one EGFR TKI (washout period = 7 days)
If most recent line of treatment (1st or 2nd line) was a third-generation EGFR
TKI (e.g. osimertinib)
Patient must be known to be EGFR mutation positive, either on fresh tumour biopsy taken >7 days prior to protocol treatment start or by recent ctDNA analysis (informative ctDNA test, local test)
T790M genotype is allowed
If most recent line of treatment (1st or 2nd line) was a first- or second-generation
EGFR TKI (e.g. afatinib, dacomitinib, erlotinib, gefitinib)
Patient must be known to be tissue EGFR T790M wild type (local test) on most recent
Haemoglobin greater or equal 90 g/L
line of EGFR TKI or if no tissue re-biopsy, no evidence of T790M on ctDNA but
identified L858R, del19, S768I or G719X genotypes (informative ctDNA test, local test)
Treatment with an EGFR TKI therapy for at least 30 days
Adequate haematological function
Absolute neutrophils count (ANC) greater or equal 1.5× 109/L
Platelet count greater or equal 100× 109/L
Adequate renal function
• Creatinine clearance greater or equal 45 mL/min (using the Cockcroft-Gault formula)
Adequate liver function
ALT and AST less or equal 2.5× ULN. If the patient has liver metastases, ALT and
AST must be less or equal 5× ULN
Total bilirubin less or equal 1.5x ULN
Willingness to provide any surplus tumour sample obtained at the time of acquired
resistance to prior EGFR TKI
Men and women of childbearing potential must agree to use adequate contraception
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Life expectancy greater or equal 12 weeks
Women of childbearing potential, including women who had their last menstrual period
in the last 2 years, must have a negative serum or urine pregnancy test within 7 days
before randomisation
Patient is willing and able to comply with the protocol for the duration of the trial
including undergoing treatment and scheduled visits and examinations including follow
up

Exclusion Criteria

Prior therapy with bevacizumab or other anti-angiogenic agent
Prior immune checkpoint inhibitor therapy
More than two lines of EGFR TKI therapy
Squamous cell histologic subtype
Active or untreated CNS metastases as determined by brain MRI
Clear tumour infiltration into the thoracic great vessels (seen on imaging)
Active or uncontrolled HIV, tuberculosis, hepatitis B or C infection
Live attenuated vaccination within 4 weeks prior to randomisation
Prior systemic cytotoxic chemotherapy for advanced stage NSCLC Patients who had
received previous adjuvant or neoadjuvant chemotherapy are eligible if the last dose
Anti-hypertensive therapy to achieve these parameters is allowable
of treatment was at least 12 months before randomisation
Prior history of hypertensive crisis or hypertensive encephalopathy
Known small-cell lung carcinoma (SCLC) or high grade neuroendocrine carcinoma (if
progression biopsy has been performed locally)
Known EGFR T790M positive genotype by tissue on most recent EGFR TKI progression or
ctDNA and have not received an approved EGFR TKI targeting T790M (e.g. a
third-generation EGFR TKI such as osimertinib)
Patients with CNS metastases must be non-progressive by RECIST v1.1 and
symptomatically stable with no ongoing requirement for corticosteroids as therapy for
CNS disease; anticonvulsants at a stable dose allowed
Serious, non-healing wound, active ulcer, or untreated bone fracture
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of
radiation within 4 weeks of randomization
Presence or history of a malignant disease that has been diagnosed and/or required
therapy within the past 3 years. Exceptions to this exclusion include the following
completely resected basal cell and squamous cell skin cancers, and completely resected
carcinoma in situ of any type
Women who are pregnant or in the period of lactation
QTc of grade ≥3 according to CTCAE v5.0
Active autoimmune disease that has required systemic treatment in past 2 years
Patients with vitiligo, controlled type I diabetes mellitus on stable insulin, or
residual autoimmune-related hypothyroidism only requiring hormone replacement or
psoriasis not requiring systemic treatment are permitted
History of active diverticulitis
Subject receiving any biologic drugs targeting the immune system (for example, TNF
blockers, anakinra, rituximab, abatacept, or tocilizumab) within 6 weeks prior to
treatment start
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
chest computed tomography scan. History of radiation pneumonitis in the radiation
field (fibrosis) is permitted
Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg
and/or diastolic blood pressure >100 mmHg)
Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent
peripheral arterial thrombosis) within 6 months prior to randomization
History of haemoptysis (greater or equal 2.5mL of bright red blood per episode) within
month prior to randomization
Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic
anticoagulation)
Current or recent (within 10 days before randomization) use of aspirin (>325 mg/day)
or treatment with dipyramidole, ticlopidine, clopidogrel, and clostazol
Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for
therapeutic purposes that has not been stable for >2 weeks prior to randomization
The use of full-dose oral or parenteral anticoagulants is permitted as long as
the INR or aPTT is within therapeutic limits (according to the medical standard
of the enrolling institution) and the patient has been on a stable dose of
anticoagulants for at least 2 weeks prior to randomization
Prophylactic anticoagulation for the patency of venous access devices is allowed
provided the activity of the agent results in an INR <1.5× ULN and aPTT is within
normal limits within 14 days prior to randomization
Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is
permitted
Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to the first dose of bevacizumab
Major surgery or significant traumatic injury 28 days prior to the first dose of
bevacizumab
Minor surgical procedure within 7 days, or placement of a vascular access device
days prior to the first dose of bevacizumab
History of abdominal or tracheoesophageal fistula or gastrointestinal perforation
within 6 months prior to randomization
Clinical signs of gastrointestinal obstruction or requirement for routine parenteral
hydration, parenteral nutrition, or tube feeding
Evidence of abdominal free air not explained by paracentesis or recent surgical
procedure
Proteinuria, as demonstrated by urine dipstick or >1.0 g of protein in a 24-hour urine
collection
All patients with greater or equal 2+ protein on dipstick urine analysis at baseline
must undergo a 24 hour urine collection and must demonstrate lesser or equal 1 g of
protein in 24 hours
Any unresolved toxicities from prior therapy greater than CTCAE v5.0 grade 1 at the
time of starting trial treatment with the exception of alopecia
History of hypersensitivity to the known active substances (atezolizumab, bevacizumab
and chemotherapy drugs) or to any of the excipients
History of hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other
recombinant human or humanised antibodies
Judgment by the Investigator that the patient should not participate in the study if
the patient is unlikely to comply with study procedures, restrictions and
requirements
Sexually active men and women of childbearing potential who are not willing to use an
effective contraceptive method during the trial and up to 6 months after discontinuing
trial treatment
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note